Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Despite the promising results with current approved immunotherapies, all patients do not have the same level of response, and recent efforts have focused on understanding and avoiding immunotherapy resistance. Our lab and others have recently proposed that the metabolic state of tumor infiltrating lymphocytes, either preexisting or adoptively transferred, can compromise T cell function and consequently antitumor immunity. This suggests that the understanding of metabolic mediators and systemic metabolic disorders can contribute to the improvement of current immunotherapies as well as understanding therapeutic responses. Furthermore, understanding the mechanism of action in metabolic disorders can allow us to harness their inflammatory potential. Leptin affects a wide range of metabolic processes as well as being a pro inflammatory mediator, can be utilized as a means to remodel the metabolic state of the tumor microenvironment, consequently modulating immunotherapy response. Our data shows that leptin overexpressing tumors have increased T cell infiltration compared to control tumors, and these TIL are metabolically and functionally superior. We next wanted to translate tumor-specific expression of leptin into a therapeutic model. Oncolytic viruses are an attractive therapeutic modality promoting tumor specific killing, inducing an anti-tumor immune response, as well as the capacity to deliver genetic payloads potentially enhancing their anti-tumor activity. We designed an oncolytic Vaccinia virus that expresses leptin and used it to treat aggressive genetically-induced melanomas. While wild-type oncolytic Vaccinia showed some response, leptin-engineered Vaccinia had superior therapeutic efficacy inducing complete regressions in 30% of mice. TIL from these tumors have improved T cell infiltration and function. Single cell RNAseq and TCR sequencing immune infiltrates revealed the influx of new T cells by vaccinia while leptin-expressing virus showed specific clonal expansion. Most importantly we observed a strong memory response when complete responders where rechallenged with tumor cells. Taken together, these data suggest that understanding metabolic modulators in metabolic disorders, like leptin, can inform on therapeutic outcomes as well as taking advantage of these molecules for novel therapeutic modalities.

Learning Objectives:

1. Understand the role metabolic pressures play on the function of tumor infiltrating lymphocytes.

2. Identify metabolic mediators as potential therapeutic targets.

3. Learn about oncolytic viruses and their mechanisms of action as immunotherapeutic modalities.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
Loading Comments...
Show Resources